Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

作者：Louise Kathleen Kostos, James Patrick Buteau, Jing Xie, Anthony Cardin, Tim J. Akhurst, Ramin Alipour, Lewis Au, Joanna Sue Yee Chan, Kwang Chin, Brittany Emmerson, Luc Furic, Q. F. B. Rodríguez García, Anthony J Hamilton, Mohammad B. Haskali, Price A Jackson, Raghava K Kashyap, Grace Kong, Lisa MacFarlane, Declan G. Murphy, Belinda S. Parker, Aravind S. Ravi Kumar, Javad Saghebi, Yang Wang, Ben Tran, Arun Azad, Michael S. Hofman · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00559-5 · 被引用次数：19 · 研究领域：Prostate Cancer Treatment and Research、Radiopharmaceutical Chemistry and Applications、Prostate Cancer Diagnosis and Treatment